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Currently less than about 5% of individuals requiring anti-
retroviral therapy (ART) can access these medicines in a
resource-poor setting. In South Africa there are at least 4.7
million HIV-positive individuals, each of whom has a right to
therapy. Access to ART has, however, been limited locally to
that minority of individuals fortunate enough either to be able
to afford to pay independently, or to have entered sponsored
programmes of HIV/AIDS disease management. Sponsorship
may be related to pharmaceutical drug trials, grant-funded
programmes, or HIV/AIDS programmes offered by employers.
To parallel ART initiatives, laboratory monitoring of varying
degrees is essential to ensure that safety is not compromised in
individuals taking ART drugs. Despite recent substantial
decreases in ART costs (in some instances free drugs),
expensive laboratory testing may still be a limiting factor in the
implementation of ART programmes.
Laboratory monitoring of HIV/AIDS could potentially
represent a significant challenge to any Third World country,
where the total cost of disease monitoring may exceed an
annual health budget. Most developing countries are grossly
under-resourced, with annual health expenditure per capita
frequently less than the current cost of a single viral load assay.
The monitoring algorithms utilised for HIV management based
on international guidelines1 are regarded by some as an
‘overkill’ and inappropriate for use in our local setting.2,3
Although local innovation offers new hope 4 of bringing down
costs of laboratory monitoring, viral load testing remains
expensive and inaccessible. Handouts will always be gratefully
received for reduced manufacturing costs of reagents, 5 but
implementation of sustainable laboratory monitoring and ART
programmes will only come with further innovation and
creative collaborative efforts. This is the only way forward to
manage the HIV/AIDS epidemic in this country.
Many obstacles are noted in the provision of affordable and
accessible laboratory monitoring for HIV/AIDS in a resource-
poor setting. These include lack of or poor laboratory
infrastructure, absence of technical skill, and more specifically,
absence of or poor laboratory management skills. Reagent costs
are generally high and large capital outlay costs for
sophisticated equipment are required. The recent devaluation
of the Rand further compounds the problem of dramatically
escalating costs of imported equipment, reagents and
consumables. There is also frequently poor supplier support in
remote areas. Lastly, the restricted use of intellectual property
may prohibit use of specific technologies, or specifically,
modifications of the technologies, for use in a resource-poor
setting.
Detailed costs pertaining to running and management of
laboratories are typically underestimated and frequently
overlooked. Careful evaluation of relevant infrastructure
including related costs such as staff salaries, laboratory rentals,
equipment maintenance and sample shipping costs, as well as
costs of reagents and consumables, is  required to ensure a
sustainable laboratory infrastructure. Logistics of sample
collection and delivery of results are also very difficult,
especially in remote areas. Different laboratories have different
needs, which need to be taken into account with regard to the
specific environment. Monitoring in resource-poor settings
may further require significant modification of internationally
recommended guidelines. In some instances, writing of
relevant local guidelines may be more appropriate. The novel
use of available technology or innovative new technologies and
the establishment of affordable, effective quality control
programmes are also required. Facilitating informed decision
making for implementation of the appropriate technology is
therefore essential. This should be based on local technical
skills, laboratory resources, volumes of work, availability of
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quality control initiatives and good training programmes.
A single solution in all regions is therefore not feasible and a
tiered laboratory approach is the most practical for rapid
implementation and affordability, with primary centres
preparing and referring more specialised testing to secondary
or tertiary testing facilities (both private and public).
Secondary (or in some cases, primary) care centres may
develop the capacity to perform less sophisticated testing such
as basic chemistry and haematological analysis. In certain
instances they may utilise simple systems for CD4 enumeration
such as the manual CD4 counting bead assays (Cytospheres;
Beckman Coulter, Fla, USA, and Dynabeads; DYNAL, NY,
USA). Tertiary academic complexes and major hubs of the
private laboratories generally have the ability to perform tests
(or at least have the capacity to develop such tests), including
flow cytometric-based CD4 tests, nucleic acid amplification
techniques for viral load testing, and drug resistance and
toxicity screening.
Monitoring generally includes investigations to determine
efficacy, toxicity and therapy compliance. A great deal of
debate currently centres on how permissive antiretroviral
treatment and laboratory-monitoring strategies can be without
compromising safety. Several questions need addressing. Can
clinical parameters such as weight gain, quality of life
assessment or a reduction in complications replace laboratory
monitoring? Are there less expensive surrogate markers? Can
laboratory testing be performed less frequently? Many of these
issues are addressed in the new draft World Health
Organisation guidelines entitled ‘Guide to ART in resource
limited settings’ (http://www.who.int/HIV_AIDS/WHO_
HSI_2000.04_1.04/003. htm). This document further defines
two related but different dilemmas: the need to distinguish
between an overall public health perspective for wide-scale
implementation of ART versus individual patient management.
The document outlines the use of laboratory investigations,
divided into four categories: ( i) absolute minimum tests; 
(ii) basic recommended tests; (iii)  desirable tests; and (iv)
optional, tests (http://www.who.int/hiv/topics/arv/scaling_exe_
summary.pdf). In this guideline, a consensus was reached that
the absolute minimum requirements for initiation of therapy
should include an HIV antibody test and a haemoglobin
and/or haematocrit level. Basic recommended testing should
include a white cell count and differential count, basic liver
function assays including AST and ALT (to monitor for co-
infection with hepatitis or drug-related hepatotoxicity), serum
creatinine/urea, serum glucose, and pregnancy tests for
women. Expanded liver function profiles (including amylase,
bilirubin and lipids) and CD4 testing are considered desirable
tests. Viral load testing is considered an optional test because of
high associated costs.
Although our funding is limited, the outlook for monitoring
in South Africa appears favourable. There is a well-developed
laboratory network comprised of both the private sector and
the newly formed umbrella national laboratory service, viz. the
National HealthLaboratory Service (made up of existing
provincial and academic hospital-based facilities, the erstwhile
South African Institute for Medical Research laboratories and
other centres of excellence, e.g. the National Institute of
Virology). Centres with poor or no infrastructure for collection
of samples and delivery of results are being revitalised by
using off-road motorcycles for specimen collection, and an SMS
reporting system using the existing well-developed GSM (cell
phone) wireless networks. This local innovative concept
introduced into certain areas of the Transkei has revolutionised
a previously severely limited Transkei laboratory infrastruc-
ture, enabling remote clinics access to a laboratory service.
Requests for collection of samples can be communicated by
SMS, and facilitated by the use of off-road motorbikes that
collect the samples in remote sites and deliver them to local
laboratories. Individual patient results are sent back at very
low costs via SMS to the requesting clinic sister (web link:
www.exactmobile.com/Press/PressResults.asp?ID=32). This
system can be further enhanced by use of interactive WAP
(Wireless Application Protocol) or more powerfully by the
recently introduced General Packet Radio Service (GPRS)
standard, which will allow ultra-fast data transfer via a
continuously connected pipeline in a ‘pay per bit’ system. In
fact this latter technology holds considerable promise for viable
implementation of many of the existing telemedicine
applications that previously failed because of their reliance on
telephone landlines and expensive, proprietary hardware and
software.
In conclusion, there are several centres of excellence across
the country, and it is unlikely that South Africa will lack the
laboratory capacity to support national rollout of ART. There
are at last 20 flow cytometry facilities across South Africa and
numerous molecular laboratories to support a national
treatment plan. The high cost of reagents still needs to be
addressed. Although some local initiatives are in place to
provide very affordable ‘generic’ monoclonal antibodies6 for
CD4 testing to contain costs in the state sector, further
initiatives are still needed to entice manufacturing companies
and other manufacturers of testing components to reduce the
costs of reagents required for testing, especially those of viral
load.
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